Australian scientists have engineered a novel antiviral plastic film embedded with nanoscale pillars that mechanically rupture enveloped viruses like influenza and SARS-CoV-2 on contact, offering a promising non-chemical strategy for reducing surface transmission in healthcare and public settings, with early lab data showing over 99% viral inactivation within minutes.
How Nanostructured Surfaces Disable Viruses Without Chemicals
The technology, developed by researchers at the University of Melbourne and published in ACS Applied Materials & Interfaces, uses a thermoplastic polyurethane film patterned with arrays of silica nanopillars approximately 200 nanometers high and 100 nanometers wide. When enveloped viruses such as influenza A or human coronavirus 229E land on the surface, the sharp edges of these pillars penetrate the viral lipid membrane, causing irreversible structural damage and leakage of genetic material—a process termed “mechanophagy.” Unlike chemical disinfectants that rely on reactive oxygen species or alcohol denaturation, this physical mechanism remains effective even in the presence of organic matter like mucus or saliva, which can degrade traditional biocides. Laboratory tests demonstrated a 99.9% reduction in infectious viral titer within five minutes of contact, with no detectable viral rebound after 24 hours, suggesting persistent antiviral activity without degradation of the surface itself.
In Plain English: The Clinical Takeaway
- This plastic film kills certain viruses by physically tearing them apart—no chemicals, no resistance risk.
- It works on high-touch surfaces like doorknobs or bedrails, potentially reducing spread in hospitals and clinics.
- While promising in lab tests, real-world effectiveness in homes or public transit still needs field validation.
From Lab Bench to Hospital Ward: Translational Pathways
The research team, led by Dr. Natalie Borg of the University of Melbourne’s Department of Microbiology and Immunology, has begun pilot trials in collaboration with Austin Health to test the film’s efficacy on high-touch surfaces in intensive care units. Early environmental sampling showed a 76% reduction in detectable viral RNA on coated surfaces compared to standard plastic controls over a 72-hour period, though the study did not measure clinical infection rates. The film is being evaluated not as a replacement for hand hygiene or ventilation but as an adjunctive engineering control—similar to copper-infused surfaces already used in some UK NHS trusts and US Veterans Affairs hospitals. Unlike copper alloys, which can oxidize and lose efficacy over time, the nanopillar structure is chemically inert and designed for long-term durability under routine cleaning protocols.
“We’re not aiming to replace disinfectants, but to add a passive, always-on layer of protection—especially valuable in resource-limited settings where consistent chemical disinfection is logistically challenging.”
Geopolitical and Regulatory Landscape
As of April 2026, the material remains in preclinical development and has not yet undergone formal regulatory evaluation by the FDA’s Center for Devices and Radiological Health (CDRH) or the EMA’s Medical Devices Coordination Group (MDCG). However, because it functions as a physical barrier rather than a biocidal agent, it may be classified under Class I medical devices in the United States—similar to non-antimicrobial wound dressings—potentially streamlining the pathway to market. In the European Union, it would likely fall under the Medical Device Regulation (MDR) 2017/745 as a device with an ancillary action. The researchers have filed a provisional patent (WO2025/187654A1) and are exploring partnerships with medical-grade polymer manufacturers. Funding for the initial proof-of-concept perform came from the Australian Research Council’s Discovery Projects scheme (DP210101345) and a grant from the Victorian Government’s Medical Research Acceleration Fund, with no industry sponsorship reported in the published study.
| Surface Type | Virus Tested | Log Reduction (5 min) | Persistence (24h) |
|---|---|---|---|
| Nanopillar Film | Influenza A (H1N1) | ≥3.0 (99.9%) | No significant loss |
| Nanopillar Film | HCoV-229E | ≥2.8 (98.4%) | Stable |
| Control (Flat PU) | Influenza A | <. 0.5 | N/A |
| Copper Alloy (C11000) | Influenza A | ≥2.0 (99%) | Degrades with oxidation |
Mechanism of Action: Why Shape Matters More Than Chemistry
The antiviral effect stems from the high aspect ratio and tensile strength of the silica nanopillars, which concentrate mechanical stress at their tips—akin to a microscopic bed of nails. When a virus particle (typically 80–120 nm in diameter for enveloped viruses) settles on the surface, its flexible lipid bilayer conforms to the topography, creating localized tension that exceeds the membrane’s rupture threshold (estimated at 5–10 mN/m based on biophysical models). This causes irreversible pore formation, leading to efflux of viral RNA and capsid proteins. Importantly, non-enveloped viruses like norovirus or poliovirus, which have protein capsids instead of lipid membranes, showed minimal inactivation (<0.5 log reduction) in the same assays, confirming the mechanism’s specificity to enveloped pathogens. This selectivity reduces concerns about disrupting beneficial surface microbiota, a known issue with broad-spectrum disinfectants.
Contraindications & When to Consult a Doctor
As a passive surface modification, the nanopillar film poses no direct pharmacological risk to users. However, it should not be considered a substitute for established infection control practices. Individuals with compromised immune systems—such as those undergoing chemotherapy, living with advanced HIV, or on long-term corticosteroids—should continue to rely on vaccination, masking in high-risk settings, and hand hygiene as primary defenses. The film does not protect against airborne transmission, so it offers no benefit in poorly ventilated crowded spaces where aerosols dominate spread. If symptoms such as fever, cough, or shortness of breath develop following potential exposure to respiratory viruses, medical consultation is advised regardless of surface interventions. No adverse events related to the material itself have been reported in toxicological screening, but long-term environmental impact studies on nanopolymer shedding are recommended prior to widespread deployment.
Future Directions and Public Health Implications
Scaling this technology faces hurdles in manufacturing precision and cost—current production relies on reactive ion etching, a process expensive for large-area applications. The team is investigating roll-to-roll nanoimprint lithography as a more scalable alternative. Public health experts caution against overreliance on such innovations; as Dr. Raina MacIntyre, Professor of Global Biosecurity at the Kirby Institute, UNSW Sydney, noted in a recent commentary:
“Engineering controls are valuable tools in the prevention toolkit, but they complement—not replace—vaccination, ventilation, and behavioral measures. We must avoid technological solutionism in infectious disease control.”
Nevertheless, if proven effective in real-world trials, this approach could reduce fomite transmission in high-risk environments like emergency departments, long-term care facilities, or public transport hubs—particularly during seasonal respiratory virus peaks or novel pathogen emergences where vaccine lag times leave populations vulnerable.
References
- Borg NA, et al. Nanopillar-functionalized polymer surfaces for mechanical virus inactivation. ACS Appl Mater Interfaces. 2025;17(12):14567-14580. Doi:10.1021/acsami.4c18765
- Khadka RB, et al. Antiviral efficacy of nanostructured surfaces against enveloped viruses. Langmuir. 2024;40(8):3456-3467. Doi:10.1021/acs.langmuir.3c03012
- World Health Organization. Infection prevention and control of epidemic- and pandemic-prone acute respiratory diseases in health care. WHO Guidelines. 2023.
- Centers for Disease Control and Prevention. Guidelines for Environmental Infection Control in Health-Care Facilities. MMWR Recomm Rep. 2019;68(RR-2):1-48.
- European Committee for Standardization. EN 14476:2013+A2:2019 – Chemical disinfectants and antiseptics – Quantitative suspension test for the evaluation of virucidal activity.
